Approval of the First Nonprescription Oral Contraceptive Pill.
Journal
Journal of obstetric, gynecologic, and neonatal nursing : JOGNN
ISSN: 1552-6909
Titre abrégé: J Obstet Gynecol Neonatal Nurs
Pays: United States
ID NLM: 8503123
Informations de publication
Date de publication:
14 Aug 2024
14 Aug 2024
Historique:
medline:
18
8
2024
pubmed:
18
8
2024
entrez:
17
8
2024
Statut:
aheadofprint
Résumé
In July 2023, the U.S. Food and Drug Administration approved Opill (norgestrel 0.075 mg), a progestin-only tablet to prevent pregnancy to be used without a prescription. Although progestin-only birth control pills were approved in 1973, it has taken 50 years for the first oral contraceptive pills to be sold over the counter. In this column, I review the evidence on the barriers to access oral contraceptive pills, the efficacy, preferences and support of a nonprescription progestin-only pill, the cost, and policy implications for health insurance coverage. I conclude with recommendations from professional organizations on over-the-counter access to hormonal contraception.
Identifiants
pubmed: 39153740
pii: S0884-2175(24)00261-2
doi: 10.1016/j.jogn.2024.08.001
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier Inc.